Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Xilio Therapeutics Inc XLO

Healthcare Biotechnology
Xilio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The Company is using its proprietary platform to advance a pipeline of novel, tumor-activated... see more

Recent & Breaking News (NDAQ:XLO)

Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors

GlobeNewswire 7 days ago

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results

GlobeNewswire 7 days ago

Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

GlobeNewswire October 30, 2024

Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

GlobeNewswire October 4, 2024

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 2, 2024

Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

GlobeNewswire August 28, 2024

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results

GlobeNewswire August 8, 2024

Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors

GlobeNewswire June 13, 2024

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results

GlobeNewswire May 14, 2024

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire April 1, 2024

Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing

GlobeNewswire March 28, 2024

Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program

GlobeNewswire March 28, 2024

Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference

GlobeNewswire February 28, 2024

Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference

GlobeNewswire January 31, 2024

Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies

GlobeNewswire January 8, 2024

Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data

GlobeNewswire December 7, 2023

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results

GlobeNewswire November 9, 2023

Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors

GlobeNewswire November 3, 2023

Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting

GlobeNewswire October 31, 2023

Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

GlobeNewswire September 27, 2023